E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response
Jie Peng,Robert P. Hasserjian,Guilin Tang,Keyur P. Patel,Maitrayee Goswami,Elias Jabbour,Guillermo Garcia-Manero,L. Jeffrey Medeiros,Sa Wang +8 more
TL;DR: Findings illustrate that ≥ 50% erythroids may appear in BM post-HMA therapy, likely a combination of reduction of BM granulocytes and promotion of normal or abnormal erythroid proliferation.
Journal ArticleDOI
Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
Paul Koller,Rima M. Saliba,Celina Ledesma,Gabriela Rondon,Uday R. Popat,Amin M. Alousi,Rohtesh S. Mehta,Betul Oran,Amanda Olson,Chitra Hosing,Muzaffar H. Qazilbash,Issa F. Khouri,Stefan O. Ciurea,Elizabeth J. Shpall,Jeffrey L. Jorgensen,Sa Wang,Nitin Jain,Elias Jabbour,Hagop M. Kantarjian,Richard E. Champlin,Marina Konopleva,Partow Kebriaei +21 more
Journal ArticleDOI
Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
TL;DR: The most relevant data related to blinatumomab in ALL is reviewed, which shows efficacy in ALL with minimal residual disease, relapsed/refractory ALL, and NHL in phase I and II clinical trials.
Journal ArticleDOI
Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.
Gautam Borthakur,Farhad Ravandi-Kashani,Jorge E. Cortes,Elias Jabbour,Stefan Faderl,Susan O'Brien,Srdan Verstovsek,Guillermo Garcia-Manero,Beth Newman,Francis J. Giles,Jean Pierre J. Issa,Hagop M. Kantarjian +11 more
TL;DR: Decitabine is active in MDS following failure of azacitidine therapy and comparisons to one drug after treatment failure with the other may offer evidence for superior efficacy.
Journal ArticleDOI
GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis.
Paul Koller,Hui Zhang,Hagop M. Kantarjian,Elias Jabbour,Sherry Pierce,Yoshihiro Gocho,Kathryn G. Roberts,Wenjian Yang,Charles G. Mullighan,Jun J. Yang,Marina Konopleva,Nitin Jain +11 more